Influenza A/H5N1 Vaccine Clinical Trial (IVACFLU-A/H5N1) - Phase 1

Inclusion Criteria: * Male or female adult 18 through 30 years of age at the enrollment visit. * Literate and willing to provide written informed consent. * Healthy adults, as established by the medical history and screening evaluations, including physical examination. * Capable and willing to complete diary cards and willing to return for all follow-up visits. * For females, willing to utilize reliable birth control measures (intrauterine device, hormonal contraception, condoms) through the Day 42 visit Exclusion Criteria: * Participation in another clinical trial involving any therapy within the previous three months or planned enrollment in such a trial during the period of this study. * Receipt of any non-study vaccine within four weeks prior to enrollment or refusal to postpone receipt of such vaccines until after the Day 42 visit. * Current or recent (within two weeks of enrollment) acute illness with or without fever. * Receipt of immune globulin or other blood products within three months prior to study enrollment or planned receipt of such products prior to the Day 42 visit. * Chronic administration (defined as more than 14 consecutively-prescribed days) of immunosuppressants or other immune-modulating therapy within six months prior to study enrollment. (For corticosteroids, this means prednisone or equivalent, ≥ 0.5 mg per kg per day; topical steroids are allowed.) * History of asthma. * Hypersensitivity after previous administration of any vaccine. * Other AE f…